Lipoproteins and Cardiovascular Health
Moving in Circulation and JAMA.
- Moved, week to 18 Nov 2026
- 2
- Papers in 60 days
- 78
Rebuilt
Moved this week
AI summary · may contain errors
Elevated LDL-C accounted for 3.6 million deaths and 90.7 million DALYs in 2023, with age-standardized death and DALY rates down 45.6% and 39.5% since 1990.
- 9 cites
Latest in Lipoproteins and Cardiovascular Health
Newest first · last 60 days
AI summary · may contain errors
IgM antibodies against oxidized LDL phospholipids are linked to lower cardiovascular risk by neutralizing modified LDL and promoting its clearance, highlighting atherosclerosis-relevant immune protection.
AI summary · may contain errors
In Sweden’s acute coronary syndrome PCI population, a default prasugrel policy did not reduce 1-year ischemic events versus a default ticagrelor policy (11.1% vs 11.8%; adjusted OR 0.90).
- 1 cites
AI summary · may contain errors
The manuscript has been withdrawn after re-evaluation and refinement of the dataset and statistical analysis, and the preliminary preprint results will be substantially updated.
- Open access
AI summary · may contain errors
Hypertriglyceridaemia is linked to higher cardiovascular disease risk, with risk mediated by cholesterol in triglyceride-rich remnant particles rather than triglycerides themselves.
- Open access
AI summary · may contain errors
In the Stockholm Study, interpretable multimodal networks distinguished hepatic molecular signatures for simvastatin, ezetimibe, and their combination, while placebo produced a less multimodal, more fragmented network.
- Open access
AI summary · may contain errors
Higher white blood cell count is strongly associated with greater 6-year subclinical atherosclerosis plaque burden in 3,471 middle-aged asymptomatic participants, increasing global plaque volume by 32.6% per 1 SD.
- Open access
AI summary · may contain errors
In an open-label randomized trial of adults ≥70 years on statins for primary prevention, stopping statins was noninferior to continuing at 2 years (−2.0 weeks).
AI summary · may contain errors
Pelacarsen (80 mg monthly) did not reduce major adverse cardiovascular events versus placebo in 8322 patients with preexisting cardiovascular disease and lipoprotein(a) ≥70 mg/dL.
AI summary · may contain errors
In a Northern California cohort of adults with ASCVD and LDL-C ≥70 mg/dL, lipid-lowering therapy was not escalated in 11,842 of 13,354 relevant notes (88.7%).
- Open access
AI summary · may contain errors
In adults with atherosclerotic cardiovascular disease, chronic kidney disease, and high-sensitivity CRP ≥2 mg/L, ziltivekimab did not reduce 3-point MACE versus placebo (HR 0.99).
AI summary · may contain errors
Lower achieved LDL cholesterol after statin initiation in 185,237 primary-prevention patients is linked to reduced major adverse cardiovascular events, with the strongest contrast versus LDL ≥2.6 mmol/L.
- Open access
AI summary · may contain errors
In the National Cancer Institute–Kaiser Permanente Breast Cancer Survivors Cohort, statin therapy vs usual care showed no clear difference in 5-year CVD risk (risk ratio 1.04, 95% CI 0.86–1.25).
- Open access
AI summary · may contain errors
In 24 individuals with type 2 diabetes, dapagliflozin (10 mg/day) for 6 months does not change LDL-ApoB100 fractional catabolism (0.88 ± 0.37 vs 0.79 ± 0.31 pool/day; p=0.16).
AI summary · may contain errors
Higher measured lipoprotein(a) levels are associated with incident venous thromboembolism in this cohort study, quantifying risk across participants.
- Open access
- 1 cites
AI summary · may contain errors
More intensive lipid-lowering therapy (rosuvastatin 40 mg plus ezetimibe 10 mg) produced greater coronary plaque regression than intensive therapy in statin-naive stable CAD, with TPV reduction -69.8 mm3 vs -39.0 mm3 at 18 months.
AI summary · may contain errors
Co-expression of ANGPTL8 with both ANGPTL3 fragments A3-FL and A3-Nter is required for maximal lipoprotein lipase inhibition, as shown in mouse liver and lipid studies.
- Open access
AI summary · may contain errors
In the multiethnic HELIUS cohort, having elevated LDL-C, Lp(a), and hsCRP together is linked to a 2.44-fold higher incident ASCVD risk over 8.9 years.
- Open access
- 4 cites
AI summary · may contain errors
Oral ruvonoflast (225 mg twice daily) in high-risk participants with hsCRP ≥2.5 mg/L and BMI 30–40 kg/m² reduced hsCRP by 82.2% at Day 28 versus 37.2% with placebo.
- Open access
- 11 cites
Browse JClub
Journals this month
- bioRxiv6524
- medRxiv1747
- PNAS583
- JAMA366
- Sci Adv330
- Cell Rep321
- Environ Res230
- BMJ216
- EHJ208
- NAR176
- Plant Cell Environ173
- Nat Commun166
- Science152
- Environ Pollution151
- NEJM148
- New Phytol148
- Lancet129
- Nature127
Topics moving, week to 18 Nov 2026
- Gut microbiota and health9
- Single-cell and spatial transcriptomics6
- CAR-T cell therapy research4
- Global Cancer Incidence and Screening3
- Lung Cancer Treatments and Mutations3
- Pancreatic and Hepatic Oncology Research3
- Antibiotic Resistance in Bacteria3
- Bacteriophages and microbial interactions3
- Diabetes Management and Education3
- Immune cells in cancer3
By field
- General Science & Medicine22
- Clinical Medicine25
- Cardiology & Vascular Biology12
- Endocrinology & Metabolism10
- Gastroenterology & Hepatology7
- Public & Global Health4
- Cell & Molecular Biology30
- Immunology & Inflammation14
- Neuroscience14
- Psychiatry & Mental Health8
- Genomics & Bioinformatics29
- Pharmacology & Drug Discovery5
- Microbiology & Mycology34
- Oncology22
- Ecology & Evolution5
- Protected Cropping & Horticultural Science5
- Plant Physiology & Photobiology19
- Student Research1
